Search Drug Information, Interactions, Images, Dosage & Side Effects

Ibrutinib-bendamustine-rituximab combo promising for older patients with mantle-cell lymphoma 30 Jun 2022

A treatment combination comprising the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus bendamustine and rituximab, followed by rituximab maintenance therapy, improved progression-free survival (PFS) in older patients with untreated mantle-cell lymphoma, according to results of the SHINE* trial presented at ASCO 2022.

Poor glycaemic control tied to COVID-19 progression

30 Jun 2022

Persistent ALT elevation triples risk of future T2D among overweight, obese children

30 Jun 2022

Medication-assisted therapy tied to arrhythmia in patients with opioid use disorder

30 Jun 2022

Methotrexate proven safe, effective as first-line immunomodulator in paediatric Crohn's disease

30 Jun 2022

Optimism helps prevent cardiovascular disease, death

30 Jun 2022

COVID-19 shots for tots OK’d

30 Jun 2022

Thyroidectomy for PTMC: less complications, more recurrence with partial vs total removal

30 Jun 2022

High leucine tied to worse executive function in kids

30 Jun 2022

Antioxidant cocktail works against diabetic polyneuropathy in T2D

30 Jun 2022

Cardiac conduction disturbances common after placement of new-generation aortic valves

30 Jun 2022

แอ๊บบอต ประเทศไทย เปิดตัว ‘Ensure Gold HMB’ อาหารทางการแพทย์สูตรปรับปรุงใหม่ล่าสุดที่มี HMB เป็นส่วนประกอบ 27 Jun 2022;

บริษัท แอ๊บบอต ลาบอแรตอรีส จำกัด จัดงานสัมมนา นำเสนอ ‘เอนชัวร์ โกลด์’ อาหารสูตรครบถ้วนเสริม เอช เอ็ม บี พร้อมวิตามิน แร่ธาตุ และใยอาหาร อาหารทางการแพทย์สูตรปรับปรุงใหม่แบบครบถ้วนที่มี เอช เอ็ม บี (HMB หรือ beta-hydroxy-beta-methylbutyrate) เป็นส่วนประกอบ

The use of second-generation antihistamine in children with allergic rhinitis

Prof. Dr. Orapan Poachanukoon, 20 Jun 2022

Product Highlight - Ensure Gold

17 Jun 2022

Product Highlight - Tabrecta

17 Jun 2022

Ensure Gold

Contents : Complete, balanced nutrition w/ Ca β-hydroxy-β-methylbutyrate (CaHMB), dietary fiber (FOS), vit & minerals. Protein 17% (from whey, casein, soy protein isolate), fat 30% (from high oleic sunflower oil, soy oil & canola oil), carbohydrate 53% (from corn syrup solid, sucrose, FOS). Ensure Gold (vanilla flavor) Per 100 g Protein 17.33 g, fat 14 g, carbohydrate 56.42 g, fiber (FOS) 4 g, CaHMB 1,220 mg. Osmolarity: 445 mOsm/L. Energy: 432 kCal; wheat flavor Per 100 g Protein 17.33 g, fat 14 g, carbohydrate 56.42 g, fiber (FOS) 4 g, CaHMB 1,210 mg. Osmolarity: 445 mOsm/L. Energy: 432 kCal; chocolate flavor Per 100 g Protein 17.34 g, fat 14 g, carbohydrate 55.45 g, fiber (FOS) 3.8 g, CaHMB 1,230 mg. Osmolarity: 434 mOsm/L. Energy: 431 kCal; strawberry flavor Per 100 g Protein 17.34 g, fat 14 g, carbohydrate 56.58 g, fiber (FOS) 4.1 g, CaHMB 1,230 mg. Osmolarity: 434 mOsm/L. Energy: 433 kCal; coffee flavor Per 100 g Protein 17.33 g, fat 14 g, carbohydrate 56.42 g, fiber (FOS) 4 g, CaHMB 1,220 mg. Osmolarity: 445 mOsm/L. Energy: 432 kCal

Indications/Uses : Sole source of nutrition or meal supplement suitable for elderly w/ malnutrition or at risks of malnutrition.

Semglee

Contents : Insulin glargine

Indications/Uses : DM in adults, adolescents & childn ≥2 yr.

Ketesse

Contents : Dexketoprofen trometamol

Indications/Uses : Symptomatic treatment of mild to moderate pain eg, musculoskeletal pain, dysmenorrhoea, dental pain.

Hulio

Contents : Adalimumab

Indications/Uses : Monotherapy or in combination w/ MTX &/or DMARDs for moderate to severe active RA in adult patients. Monotherapy or in combination w/ MTX for active polyarticular juvenile idiopathic arthritis (pJIA) in patients from 2 yr. Active enthesitis-related arthritis in patients ≥6 yr. Adults w/ severe active ankylosing spondylitis (AS); axial spondyloarthritis. Moderate to severe chronic plaque psoriasis; active Crohn's disease & ulcerative colitis. Non-infectious intermediate, posterior & panuveitis. Severe chronic plaque psoriasis in childn & adolescents from 4 yr. Active moderate to severe hidradenitis suppurativa in adults from 12 yr. Moderate to severe active Crohn's disease in ped patient from 6 yr. Ped chronic non-infectious anterior uveitis in patients from 2 yr.

Rybelsus

Contents : Semaglutide

Indications/Uses : Adjunct to diet & exercise to improve glycaemic control in adults w/ insufficiently controlled type 2 DM as monotherapy when metformin is inappropriate due to intolerance or contraindications; in combination w/ other medicinal products for diabetes.

Tagrisso

Contents : Osimertinib

Indications/Uses : 1st-line treatment of patients w/ locally advanced or metastatic non-small cell lung cancer (NSCLC) w/ activating epidermal growth factor receptor (EGFR) mutations. Locally advanced or metastatic EGFR T790M mutation-positive NSCLC. Adjuvant therapy after tumour resection in patients w/ NSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.

Yulareb

Contents : Abemaciclib

Indications/Uses : Monotherapy in adults w/ hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer w/ disease progression following endocrine therapy & prior chemotherapy in the metastatic setting. In combination w/ aromatase inhibitor as initial endocrine-based therapy for postmenopausal women w/ HR-positive, HER2-negative advanced or metastatic breast cancer; w/ fulvestrant for women w/ HR-positive, HER2-negative advanced or metastatic breast cancer w/ disease progression following endocrine therapy.

Tabrecta

Contents : Capmatinib

Indications/Uses : Adults w/ metastatic NSCLC w/ a MET exon 14 skipping mutation.

Xyntha

Contents : Moroctocog alfa (recombinant coagulation factor VIII)

Indications/Uses : On-demand treatment & control of bleeding episodes; perioperative management; routine prophylaxis to reduce the frequency of bleeding episodes in adults & childn w/ hemophilia A (congenital factor VIII deficiency).

Saxenda

Contents : Liraglutide

Indications/Uses : An adjunct to a reduced-calorie diet & increased physical activity for wt management in adults w/ an initial BMI of ≥30 kg/m² (obesity), or ≥27 kg/m² to <30 kg/m² (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea. An adjunct to a healthy nutrition & increased physical activity for wt management in adolescents ≥12 yr w/ obesity (BMI corresponding to ≥30 kg/m² for adults by international cut-off points) & body wt >60 kg.

New Molecule

4 New

New Indication

6 New

New Presentation

2 New

New Brand

17 New

pill identifier

Shape

Form

Color 1

Color 2

Markings

Shape

Form

Color 1

Color 2

Search Drug Information, Images & Medical News | MIMS Thailand

Ensure Gold

Semglee

Ketesse

Hulio

Rybelsus

Tagrisso

Yulareb

Tabrecta

Xyntha

Saxenda